Ionis Pharmaceuticals (IONS) PT Raised to $77 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Goldman Sachs Reiterates Sell Rating on Ionis Pharmaceuticals (IONS)
July 22, 2024 12:04 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Sell rating and $33.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).
The analyst comments "Ahead of the 2024 Angelman Syndrome Foundation conference, IONS reported six-month Ph1/2 data on antisense oligonucleotide (ASO) ION582 in Angelman syndrome (n=11, 13 and 27 at the low, medium and high doses), where 67% of medium/high-dose patients improved vs. natural history,... More
Ionis Pharmaceuticals (IONS) announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
July 22, 2024 7:03 AM EDTIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS) demonstrating consistent and encouraging clinical improvement on measures assessing all functional domains including communication, cognition and motor function. Overall, 97% of people in the medium and high dose... More
